Anti-adipogenic Constituents from Dioscorea opposita in 3T3-L1 Cells

  • Yang Min Hye
    College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University
  • Chin Young-Won
    College of Pharmacy, Dongguk University–Seoul
  • Chae Hee-Sung
    College of Pharmacy, Dongguk University–Seoul
  • Yoon Kee Dong
    College of Pharmacy, The Catholic University of Korea
  • Kim Jinwoong
    College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University

書誌事項

タイトル別名
  • Anti-adipogenic Constituents from <i>Dioscorea opposita</i> in 3T3-L1 Cells

この論文をさがす

抄録

We previously reported the lipase inhibitory activity of the n-BuOH fraction of Dioscorea opposita (DOB) and its isolates. This study sought to evaluate their anti-adipogenic activity in terms of their effects on the adipogenic transcription factors peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα) as well as phosphorylated AMP-activated protein kinase (p-AMPK) and carnitine palmitoyl transferase-1 (CPT-1). DOB apparently attenuated 3T3-L1 adipocyte differentiation (33.6% decrease at 20 µg/mL). In addition, a marked decrease (90.4%) in the expression of PPARγ was observed in the DOB-treated 3T3-L1 cells. Four isolates from DOB: (4E,6E)-1,7-bis(4-hydroxyphenyl)-4,6-heptadien-3-one (1), (3R,5R)-1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanediol (2), batatasin I (3), and (1E,4E,6E)-1,7-bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one (4), suppressed adipocyte differentiation by inhibiting PPARγ at 20 µM (85.9%, 68.6%, 76.2%, and 90.2% decrease, respectively) and C/EBPα (51.7%, 3.1%, 20.9%, and 59.8% decrease, respectively). Batatasin I was found to increase p-AMPK and CPT-1 at a concentration of 20 µM in 3T3-L1 adipocytes, resulting in inhibiting adipogenesis. Taken together, batatasin I might be responsible for the anti-adipogenic effect of DOB via inhibition of PPARγ and C/EBPα and activation of p-AMPK and CPT-1.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (30)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ